Amgen (AMGN) and AstraZeneca (AZN) report that their phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75), and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment.
Shares of both companies are flat in after-hours trade.
Latest posts by Anne-Marie Jackson (see all)
- ‘Liquid Biopsy’ Shows Promising Results In Cancer Detection - Aug 19, 2017
- Antarctica Might Be Home To Around 100 Volcanoes - Aug 16, 2017
- Walmart Issues An Apology For Back-To-School And Guns Mishap - Aug 11, 2017